ARIUS announces allowance of US patent for lead anti-cancer antibody



    TORONTO, Aug. 1 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
announced today that the Company has received notice from the United States
Patent and Trademark Office that a key patent for its lead anti-CD44 drug
candidate will issue on August 7th, 2007, as US Patent Number 7,252,821. This
pivotal patent covers the ARH460-16-2 antibody itself, as well as the use of
the antibody in the treatment of breast cancers. ARIUS now has 16 issued and
allowed patents covering its antibody programs and discovery platform and over
150 patents pending.
    The ARH460-16-2 antibody drug is in development by ARIUS for breast,
prostate and liver cancers. The CD44 antigen that is targeted by this antibody
has been identified as a cancer stem cell marker in several different
malignancies. The discovery of cancer stem cells and the markers that
distinguish this population of cancer cells from others represent a key
advancement in the understanding of cancer. Such insights can be used to
develop drugs, such as ARH460-16-2, to prevent the spread of cancer and extend
survival in cancer patients. Recently ARIUS has also announced the initiation
of a toxicology program in preparation for human clinical trials.
    "ARIUS is having an extremely successful year," said Dr. David Young,
President and CEO. "We have hit a number of critical technical milestones and
the ongoing success of our patent strategy reflects the value we are building
in the company. We are moving ahead to file our IND application and begin
human clinical trials in 2008 with the U.S. FDA."
    The Company also disclosed the departure of Dr. Robert Gundel, Chief
Scientific Officer, from ARIUS.

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than
400 antibody candidates. In addition to the antibodies it is developing
in-house, ARIUS has ongoing partnerships with key biotechnology and drug
development companies. ARIUS is listed on the TSX under the symbol "ARI". For
further information, visit www.ariusresearch.com

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00013708E




For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
wwhitehead@ariusresearch.com, contact@ariusresearch.com; James Smith, Investor
Relations, (416) 815-0700 ext. 229, jsmith@equicomgroup.com

Organization Profile

ARIUS RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890